{"id":"NCT02449044","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia","officialTitle":"International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia: Extension to Studies 156-02-235 and 156-03-238 to Assess One-year Safety","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-05","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2015-05-20","resultsPosted":"2016-01-21","lastUpdate":"2016-01-21"},"enrollment":111,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hyponatremia"],"interventions":[{"type":"DRUG","name":"Tolvaptan","otherNames":[]}],"arms":[{"label":"Tolvaptan","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety of long-term tolvaptan use in patients previously enrolled in shorter-term Phase 3 studies and gather information on the natural history of hyponatremia in the context of tolvaptan therapy and underlying disease states.","primaryOutcome":{"measure":"Participants With Adverse Events (AEs)","timeFrame":"Baseline to Post-Week 214 follow-up visit","effectByArm":[{"arm":"Tolvaptan","deltaMin":105,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20185637"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":76,"n":111},"commonTop":["Oedema peripheral","Diarrhoea","Nausea","Urinary tract infection","Hyponatraemia"]}}